Download Citation
Article Source:
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
Jackson GH,
Pawlyn C,
Cairns DA,
de Tute RM,
Hockaday A,
et al.
(2021)
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLOS Medicine 18(1): e1003454.
https://doi.org/10.1371/journal.pmed.1003454